In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6

Researchers report that antiviral agents remdesivir, molnupiravir, and nirmatrelvir and monoclonal antibodies bebtelovimab and imdevimab retain effectiveness against the BA.4.6 subvariant in vitro.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-12, Vol.387 (22), p.2094-2097
Hauptverfasser:	Takashita, Emi, Yamayoshi, Seiya, Halfmann, Peter, Wilson, Nancy, Ries, Hunter, Richardson, Alex, Bobholz, Max, Vuyk, William, Maddox, Robert, Baker, David A., Friedrich, Thomas C., O’Connor, David H., Uraki, Ryuta, Ito, Mutsumi, Sakai-Tagawa, Yuko, Adachi, Eisuke, Saito, Makoto, Koga, Michiko, Tsutsumi, Takeya, Iwatsuki-Horimoto, Kiyoko, Kiso, Maki, Yotsuyanagi, Hiroshi, Watanabe, Shinji, Hasegawa, Hideki, Imai, Masaki, Kawaoka, Yoshihiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Viral - immunology Antiviral agents Antiviral Agents - immunology Antiviral Agents - pharmacology Coronavirus Coronaviruses COVID-19 - genetics COVID-19 - immunology COVID-19 - virology COVID-19 vaccines Disease transmission Drug dosages FDA approval Humans In Vitro Techniques Infectious Disease Infectious diseases Influenza Medical research Monoclonal antibodies Mutation Pathogenesis R&D Research & development RNA polymerase SARS-CoV-2 - drug effects SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Vaccine Efficacy Viral Infections
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Researchers report that antiviral agents remdesivir, molnupiravir, and nirmatrelvir and monoclonal antibodies bebtelovimab and imdevimab retain effectiveness against the BA.4.6 subvariant in vitro.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc2211845